|
1
|
Biedler JL: Drug resistance: Genotype
versus phenotype - thirty-second G. H. A. Clowes Memorial Award
Lecture. Cancer Res. 54:666–678. 1994.PubMed/NCBI
|
|
2
|
Michaelis M, Klassert D, Barth S, Suhan T,
Breitling R, Mayer B, Hinsch N, Doerr HW, Cinatl J and Cinatl J Jr:
Chemoresistance acquisition induces a global shift of expression of
aniogenesis-associated genes and increased pro-angogenic activity
in neuroblastoma cells. Mol Cancer. 8:802009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Furfaro AL, Piras S, Passalacqua M,
Domenicotti C, Parodi A, Fenoglio D, Pronzato MA, Marinari UM,
Moretta L, Traverso N, et al: HO-1 up-regulation: A key point in
high-risk neuroblastoma resistance to bortezomib. Biochim Biophys
Acta. 1842:613–622. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Cheng Y, Ren X, Zhang L, Yap KL,
Wu H, Patel R, Liu D, Qin ZH, Shih IM, et al: NAC1 modulates
sensitivity of ovarian cancer cells to cisplatin by altering the
HMGB1-mediated autophagic response. Oncogene. 31:1055–1064. 2012.
View Article : Google Scholar :
|
|
5
|
Yang S, Xu L, Yang T and Wang F:
High-mobility group box-1 and its role in angiogenesis. J Leukoc
Biol. 95:563–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang D, Kang R, Cheh CW, Livesey KM, Liang
X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, et
al: HMGB1 release and redox regulates autophagy and apoptosis in
cancer cells. Oncogene. 29:5299–5310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L, Han J, Wu H, Liang X, Zhang J, Li
J, Xie L, Xie Y, Sheng X and Yu J: The association of HMGB1
expression with clinicopathological significance and prognosis in
hepatocellular carcinoma: A meta-analysis and literature review.
PLoS One. 9:e1106262014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Süren D, Yıldırım M, Demirpençe Ö, Kaya V,
Alikanoğlu AS, Bülbüller N, Yıldız M and Sezer C: The role of high
mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit.
20:530–537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meyer A, Staratschek-Jox A, Springwald A,
Wenk H, Wolf J, Wickenhauser C and Bullerdiek J: Non-Hodgkin
lymphoma expressing high levels of the danger-signalling protein
HMGB1. Leuk Lymphoma. 49:1184–1189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brezniceanu ML, Völp K, Bösser S, Solbach
C, Lichter P, Joos S and Zörnig M: HMGB1 inhibits cell death in
yeast and mammalian cells and is abundantly expressed in human
breast carcinoma. FASEB J. 17:1295–1297. 2003.PubMed/NCBI
|
|
11
|
Wu D, Ding Y, Wang S, Zhang Q and Liu L:
Increased expression of high mobility group box 1 (HMGB1) is
associated with progression and poor prognosis in human
nasopharyngeal carcinoma. J Pathol. 216:167–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ueda M, Takahashi Y, Shinden Y, Sakimura
S, Hirata H, Uchi R, Takano Y, Kurashige J, Iguchi T, Eguchi H, et
al: Prognostic significance of high mobility group box 1 (HMGB1)
expression in patients with colorectal cancer. Anticancer Res.
34:5357–5362. 2014.PubMed/NCBI
|
|
13
|
Chen J, Liu X, Zhang J and Zhao Y:
Targeting HMGB1 inhibits ovarian cancer growth and metastasis by
lentivirus-mediated RNA interference. J Cell Physiol.
227:3629–3638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fu LL, Cheng Y and Liu B: Beclin-1:
Autophagic regulator and therapeutic target in cancer. Int J
Biochem Cell Biol. 45:921–924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang D, Kang R, Livesey KM, Cheh CW,
Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ III,
et al: Endogenous HMGB1 regulates autophagy. J Cell Biol.
190:881–892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang D, Kang R, Livesey KM, Kroemer G,
Billiar TR, Van Houten B, Zeh HJ III and Lotze MT: High-mobility
group box 1 is essential for mitochondrial quality control. Cell
Metab. 13:701–711. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in
osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar
|
|
18
|
Pan B, Chen D, Huang J, Wang R, Feng B,
Song H and Chen L: HMGB1-mediated autophagy promotes docetaxel
resistance in human lung adenocarcinoma. Mol Cancer. 13:1652014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang YH, Chen K, Li B, Chen JW, Zheng XF,
Wang YR, Jiang SD and Jiang LS: Estradiol inhibits osteoblast
apoptosis via promotion of autophagy through the ER-ERK-mTOR
pathway. Apoptosis. 18:1363–1375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang L, Zhang H, Qian J, Wang K and Zhu J:
Interleukin-10 blocks in vitro replication of human cytomegalovirus
by inhibiting the virus-induced autophagy in MRC5 cells. Biochem
Biophys Res Commun. 448:448–453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang YH, Li B, Zheng XF, Chen JW, Chen K,
Jiang SD and Jiang LS: Oxidative damage to osteoblasts can be
alleviated by early autophagy through the endoplasmic reticulum
stress pathway - implications for the treatment of osteoporosis.
Free Radic Biol Med. 77:10–20. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Murai T, Nakagawa Y, Maeda H and Terada K:
Altered regulation of cell cycle machinery involved in
interleukin-1-induced G1 and G2 phase growth
arrest of A375S2 human melanoma cells. J Biol Chem. 276:6797–6806.
2001. View Article : Google Scholar
|
|
23
|
Petiot A, Ogier-Denis E, Blommaart EF,
Meijer AJ and Codogno P: Distinct classes of phosphatidylinositol
3′-kinases are involved in signaling pathways that control
macroautophagy in HT-29 cells. J Biol Chem. 275:992–998. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moreira AC, Branco AF, Sampaio SF,
Cunha-Oliveira T, Martins TR, Holy J, Oliveira PJ and Sardão VA:
Mitochondrial apoptosis-inducing factor is involved in
doxorubicin-induced toxicity on H9c2 cardiomyoblasts. Biochim
Biophys Acta. 1842:2468–2478. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Singla S, Kumar NR and Kaur J: In vivo
studies on the protective effect of propolis on doxorubicin-induced
toxicity in liver of male rats. Toxicol Int. 21:191–195. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shokoohinia Y, Hosseinzadeh L, Moieni-Arya
M, Mostafaie A and Mohammadi-Motlagh HR: Osthole attenuates
doxorubicin-induced apoptosis in PC12 cells through inhibition of
mitochondrial dysfunction and ROS production. Biomed Res Int.
2014:1568482014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tonini GP and Pistoia V: Molecularly
guided therapy of neuroblastoma: A review of different approaches.
Curr pharm Des. 12:2303–2317. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guazzi S, Strangio A, Franzi AT and
Bianchi ME: HMGB1, an architectural chromatin protein and
extracellular signalling factor, has a spatially and temporally
restricted expression pattern in mouse brain. Gene Expr Patterns.
3:29–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Faraco G, Fossati S, Bianchi ME, Patrone
M, Pedrazzi M, Sparatore B, Moroni F and Chiarugi A: High mobility
group box 1 protein is released by neural cells upon different
stresses and worsens ischemic neurodegeneration in vitro and in
vivo. J Neurochem. 103:590–603. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reismann M, Wehrmann F, Schukfeh N,
Kuebler JF, Ure B and Glüer S: Carbon dioxide, hypoxia and low pH
lead to overexpression of c-myc and HMGB-1 oncogenes in
neuroblastoma cells. Eur J Pediatr Surg. 19:224–227. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pedrazzi M, Averna M, Sparatore B, Patrone
M, Salamino F, Marcoli M, Maura G, Cervetto C, Frattaroli D,
Pontremoli S, et al: Potentiation of NMDA receptor-dependent cell
responses by extracellular high mobility group box 1 protein. PLoS
One. 7:e445182012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wittig JC, Bickels J, Priebat D, Jelinek
J, Kellar-Graney K, Shmookler B and Malawer MM: Osteosarcoma: A
multi-disciplinary approach to diagnosis and treatment. Am Fam
Physician. 65:1123–1132. 2002.PubMed/NCBI
|
|
33
|
Mohan N, Chakrabarti M, Banik NL and Ray
SK: Combination of LC3 shRNA plasmid transfection and genistein
treatment inhibited autophagy and increased apoptosis in malignant
neuroblastoma in cell culture and animal models. PLoS One.
8:e789582013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Degenhardt K, Mathew R, Beaudoin B, Bray
K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, et al:
Autophagy promotes tumor cell survival and restricts necrosis,
inflammation, and tumorigenesis. Cancer Cell. 10:51–64. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lockshin RA and Zakeri Z: Apoptosis,
autophagy, and more. Int J Biochem Cell Biol. 36:2405–2419. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao Z, Tao L, Shen C, Liu B, Yang Z and
Tao H: Silencing of Barkor/ATG14 sensitizes osteosarcoma cells to
cisplatin-induced apoptosis. Int J Mol Med. 33:271–276. 2014.
|
|
37
|
Lanvers-Kaminsky C, Winter B, Koling S,
Frodermann B, Braun Y, Schaefer KL, Diallo R, Koenemann S, Wai D,
Willich N, et al: Doxorubicin modulates telomerase activity in
Ewing's sarcoma in vitro and in vivo. Oncol Rep. 14:751–758.
2005.PubMed/NCBI
|
|
38
|
Zhou Y, Sun K, Ma Y, Yang H, Zhang Y, Kong
X and Wei L: Autophagy inhibits chemotherapy-induced apoptosis
through downregulating Bad and Bim in hepatocellular carcinoma
cells. Sci Rep. 4:53822014.PubMed/NCBI
|
